Physical complications of recreational drug use
DOI:
https://doi.org/10.20882/adicciones.462Keywords:
recreational drugs, medical complications, hyperthermia, hepatotoxicity, treatmentAbstract
In recent years there has been an increase in the publications in the scientific literature on the toxic reactions, physical complications and deaths associated with “recreations drug” use, parallel to increase in the prevalence of this drug consumption. In addition to the adverse reactions that can be observed associated with acute intoxication, use of these substances may cause cardiovascular complications, cerebrovascular accidents, convulsions, hyponatremia leading to cerebral aedema, as well as important hepatotoxic effects. However, one of the most severe complications that may develop is a hyperthermic syndrome that may evolve to diseminated intravascular coagulation, rhabdomyolysis, and acute renal failure. The treatment of acute intoxication, in light of the absence of a specific antidote the management is primarily symptomatic and supportive.References
Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 1998; 29:394-397.
Bango J, Fadón P, Mata F, Rubio G, Santo-Domingo J. Trastornos psiquiátricos y consumo de MDMA (éxtasis): revisión de casos. Actas
Luso-Esp Neurol Psiquiatr 1998; 26:260-263.
Beitia G, Cobreros A, Sainz L, Cenarruzabeitia E. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: effect on cytosolic calcium signals in isolated hepatocytes. Liver 1999; 19:234-241.
Burgess C, O´Donohoe A, Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur Psychiatry 2000; 15:287-294.
Camí Morell J. Síntesis clandestina de drogas: pasado, presente y futuro. Med Clin (Barc) 1990; 95:344-347.
Colado MI, Lorenzo P. MDMA: farmacología y toxicología. En: Bobes J.: Éxtasis, aspectos farmacológicos, psiquiátricos y médico legales. Pp 1-46. Monografías en neurociencias n15. Ed
Neurociencias. Barcelona 1995.
Colado MI. Neurotoxicidad inducida por MDMA y su prevención farmacológica. En: Bobes y cols. Éxtasis (MDMA). Un abordaje comprehensivo. Tomo I. Pp 41-73. Colección Psiquiatría médica. Ed Masson S.A. Barcelona 1998.
Cherney DZ, Davids MR, Halperin ML. Acute hyponatremia and ecstasy: insights from a quantitative analysis. QJM 2002; 95:475-483.
Duxbury A.J. Ecstasy dental implications. Br Dent J 1993; 175:38.
Fallon JK, Shah D, Kicman AT, et al. Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci 2002; 965:399-409.
Garbino J, Henry JA, Mentha G, Romand JA. Ecstasy ingestión and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option. Vet Hum Toxicol 2001; 43:99-102.
Gowing LR, Henry-Edwards SM, Irvine RJ, Ali RL.The health effects of ecstasy: a literature review. Drug Alcohol Rev 2002; 21:53-63.
Grob CS. Investigación humana con MDMA. En Bobes y cols. Éxtasis: Un abordaje comprehensivo. Tomo I. Pp 99-106. Colección Psiquiatría médica. Ed Masson S.A. Barcelona 1998.
Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) ingestion. QJM 2002 ; 95: 431-437.
Henry JA. Ecstasy and the dance of death. Severe reactions are unpredictible. BMJ 1992; 305:5-6.
Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine. Lancet 1992; 340:384-387.
Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in Ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 1999; 13:129-133.
Kessel B. Hyponatraemia after ingestion of ecstasy. BMJ 1994; 308:414.
Lange-Brock N, Berg T, Muller AR, et al. Acute liver failure following the use of ecstasy. Z Gastroenterol 2002; 40:581-586.
Larner AJ. Dantrolene and ecstasy. Anesthesia 1993;48;179-180.
Levine AJ, Drew S, Rees GM. Ecstasy induce penumomediastinum. J R Soc Med 1993; 86:232-233.
Liester MB, Grob CS, Brabo GL, Walsh RN. Phenomenology and sequelae of 3,4-methylnedioxymethamphetamine use. J Nerv Ment Dis 1992; 180:345-352.
Llopis JJ, Farré M, Martínez-Raga J. Las drogas de diseño: clínica y tratamiento del abuso de éxtasis. En: Giner F, Cervera G (eds.) Trastornos Adictivos. Drogodependencias: clínica y tratamientos
psicobiológicos. Generalitat Valenciana. Valencia, 2001; pp.405-438.
McCann U, Slate SO, Ricaurte GA. Adverse reactions with MDMA. Drug Saf 1996; 15:107-115.
McCann UD, Ricaurte G. Aproximación a la neurobiología y neurotoxicidad comparada inducida por la MDMA. En Bobes y cols. Éxtasis (MDMA). Un abordaje comprehensivo. Tomo I.Pp 89-98. Colección Psiquiatría médica. Ed Masson S.A. Barcelona 1998.
McCann UD, Szabo Z, Scheffel U, Dannals RF,
Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA (AEcstasy@) on brain serotonin neurons in human beings.
Lancet 1998; 352:1433-1437.
McCann UD, Eligulashvili V, Ricaurte GA. (+/) 3,4-Methylenedioxymethamphetamine (‘Ecstasy’)- induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000; 42:11-6.
McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg 2000; 14:449-454.
Mechan AO, Esteban B, O’Shea E, Elliott JM, Colado MI, Green AR. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine
(MDMA, ‘ecstasy’) to rats. Br J Pharmacol 2002;135:170-180.
Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy. N Engl J Med 1999; 340:1443.
Núñez O, Banares R, Barrio J, et al. Variabilidad de la expresión clínica de la toxicidad hepática por éxtasis. Gastroenterol Hepatol 2002; 25:497-500.
Parrott AC. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001; 16:557-577.
Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (“ecstasy”). Science 2002; 297:2260-2263.
Rieder MJ. Some light from the heat: implications of rave parties for clinicians. CMAJ 2000; 162:1829-30.
Roig Traver, A: El Éxtasis, una revisión del MDMA y demás feniletilaminas psicoactivas. Libro de actas de Socidrogalcohol XVII Jornadas Nacionales. Diputación de Valencia. Área de Salud Pública.1994; pp 541-561.
Rothwell, PM, Grant R. Central nervous sinus thrombosis induced by ecstasy. J Neurol Neurosug Psychiatry 1993; 56:1035.
Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. MDMA (‘ecstasy’) consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 1998; 52:85-90.
Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH. Review of deaths related to taking ecstasy, England and Wales,
_2000. BMJ 2003; 326:80-81.
Seur C. Riduzione del danno nei rave party e tratamento delle complicación psicopatologiche. International Conferenze Ecstasy e Sostenza Psichedeliche. Ed Verso l´Utopia. Bolonia 1996; pp 116-146.
Shapiro H. A 16 Ecstasy update. Information for drug workers from ISDD. Drug Link photocopiable factsheet. ISDD, 1996.
Steele TD, McCann UD, Ricaurte GA. 3,4- Methylenedioxymmethamphetamine: pharmacology and toxicology in animals and humans. Addiction 1994; 89:539-551.
Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 2001; 21:1486-1513.
Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (Aecstasy@) in MDMA-naïve healthy volunteers. Neuropsychopharmacology 1998; 19:241-251.
